1. Discovery of new 2-phenyl-1H-benzo[d]imidazole core-based potent α-glucosidase inhibitors: Synthesis, kinetic study, molecular docking, and in vivo anti-hyperglycemic evaluation.
- Author
-
Li Y, Zhang JH, Xie HX, Ge YX, Wang KM, Song ZL, Zhu KK, Zhang J, and Jiang CS
- Subjects
- Animals, Blood Glucose analysis, Cell Line, Diabetes Mellitus, Experimental chemically induced, Diabetes Mellitus, Experimental metabolism, Dose-Response Relationship, Drug, Drug Discovery, Glycoside Hydrolase Inhibitors chemical synthesis, Glycoside Hydrolase Inhibitors chemistry, Humans, Hypoglycemic Agents chemical synthesis, Hypoglycemic Agents chemistry, Imidazoles chemical synthesis, Imidazoles chemistry, Kinetics, Molecular Structure, Rats, Streptozocin, Structure-Activity Relationship, Diabetes Mellitus, Experimental drug therapy, Glycoside Hydrolase Inhibitors pharmacology, Hypoglycemic Agents pharmacology, Imidazoles pharmacology, Molecular Docking Simulation, alpha-Glucosidases metabolism
- Abstract
In the present study, a series of 2-phenyl-1H-benzo[d]imidazole-based α-glucosidase inhibitors were synthesized and evaluated for their in vitro and in vivo anti-diabetic potential. Screening of an in-house library revealed a moderated α-glucosidase inhibitor, 6a with 3-(1H-benzo[d]imidazol-2-yl)aniline core, and then the structural optimization was performed to obtain more efficient derivatives. Most of these derivatives showed increased activity than 6a, and the most promising inhibitors were found to be compounds 15o and 22d with IC
50 values of 2.09 ± 0.04 and 0.71 ± 0.02 µM, respectively. Fluorescence quenching experiment confirmed the direct binding of compounds 15o and 22d with α-glucosidase. Kinetic study revealed that both compounds were non-competitive inhibitors, that was consistent with the result of molecular docking studies where they located at the allosteric site of the enzyme. Cell viability evaluation demonstrated the non-cytotoxicity of 15o and 22d against LO2 cells. Furthermore, the in vivo pharmacodynamic study revealed that compound 15o showed significant hypoglycemic activity and improved oral sucrose tolerance, comparable to the positive control acarbose., (Copyright © 2021 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF